MP1032
Pulmonary Fibrosis (e.g., Idiopathic Pulmonary Fibrosis)
Key Facts
About MetrioPharm
MetrioPharm is a private, clinical-stage biotech developing first-in-class oral therapeutics that modulate macrophage activity to treat inflammatory and fibrotic conditions. Its lead candidate, MP1032, is a small molecule with a unique dual mechanism targeting reactive oxygen species (ROS) and the NLRP3 inflammasome, positioning it for diseases like pulmonary fibrosis and psoriasis. The company is pre-revenue, having advanced its pipeline through private funding and strategic partnerships, and faces a competitive but high-value market with significant unmet medical need.
View full company profileAbout MetrioPharm
MetrioPharm is a private, clinical-stage biotech developing first-in-class oral therapeutics that modulate macrophage activity to treat inflammatory and fibrotic conditions. Its lead candidate, MP1032, is a small molecule with a unique dual mechanism targeting reactive oxygen species (ROS) and the NLRP3 inflammasome, positioning it for diseases like pulmonary fibrosis and psoriasis. The company is pre-revenue, having advanced its pipeline through private funding and strategic partnerships, and faces a competitive but high-value market with significant unmet medical need.
View full company profile